Cliona M Rooney

List of Publications by Year
in descending order

148 papers	15,613 citations	36271 51 h-index	19169 118 g-index
148 all docs	148 docs citations	148 times ranked	12053 citing authors

#	Article	IF	Citations
1	Epstein Barr virusâ€“positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Advances, 2022, 6, 891-901.	2.5	2
2	Donor-derived multiple leukemia antigenâ€“specific T-cell therapy to prevent relapse after transplantÂin patients with ALL. Blood, 2022, 139, 2706-2711.	0.6	13
3	A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. Cancer Immunology Research, 2022, 10, 512-524.	1.6	12
4	Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood, 2022, 140, 16-24.	0.6	14
5	Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211071.	1.4	6
6	Adoptive T-Cell Therapy for Epstein-Barr Virusâ€“Related Lymphomas. Journal of Clinical Oncology, 2021, 39, 514-524.	0.8	18
7	CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood, 2021, 138, 318-330.	0.6	98
8	T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. Journal of Clinical Oncology, 2021, 39, 1415-1425.	0.8	30
9	The National Heart, Lung, and Blood Instituteâ€funded Production Assistance for Cellular Therapies (PACT) program: Eighteen years of cell therapy. Clinical and Translational Science, 2021, 14, 2099-2110.	1.5	1
10	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Annals of Hematology, 2021, 100, 2529-2539.	0.8	12
11	Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL. Blood, 2021, 138, 471-471.	0.6	0
12	Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma. Blood, 2021, 138, 1763-1763.	0.6	6
13	Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. Journal of Clinical Oncology, 2020, 38, 3794-3804.	0.8	235
14	Identification of protective T-cell antigens for smallpox vaccines. Cytotherapy, 2020, 22, 642-652.	0.3	10
15	Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. Leukemia, 2020, 34, 3310-3322.	3.3	64
16	A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma. Blood, 2020, 136, 16-16.	0.6	6
17	A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells. Journal of Translational Medicine, 2019, 17, 240.	1.8	18
18	T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptorâ€“Expressing T Cells. Clinical Cancer Research, 2019, 25, 7340-7350.	3.2	32

#	Article	IF	Citations
19	Tâ€cell receptor sequencing demonstrates persistence of virusâ€specific T cells after antiviral immunotherapy. British Journal of Haematology, 2019, 187, 206-218.	1.2	29
20	Current challenges for CAR Tâ€cell therapy of acute myeloid leukemia. Transfusion, 2019, 59, 1171-1173.	0.8	7
21	Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy, 2019, 21, 212-223.	0.3	16
22	NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunology Research, 2019, 7, 363-375.	1.6	180
23	CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC Toxicity. Blood, 2019, 134, 1932-1932.	0.6	3
24	Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo. Nature Communications, 2018, 9, 1325.	5.8	16
25	Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Molecular Therapy - Methods and Clinical Development, 2018, 8, 131-140.	1.8	49
26	Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 1128-1139.	0.8	137
27	Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells. Frontiers in Medicine, 2018, 5, 343.	1.2	12
28	EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood, 2018, 132, 2351-2361.	0.6	49
29	InÂVivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkinâ€™s Lymphomas. Molecular Therapy, 2018, 26, 2727-2737.	3.7	180
30	Modeling cytokine release syndrome. Nature Medicine, 2018, 24, 705-706.	15.2	18
31	A New Method for Reactivating and Expanding T Cells Specific for Rhizopus oryzae. Molecular Therapy - Methods and Clinical Development, 2018, 9, 305-312.	1.8	24
32	Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opinion on Biological Therapy, 2018, 18, 653-664.	1.4	26
33	CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL). Blood, 2018, 132, 680-680.	0.6	20
34	Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Molecular Therapy, 2017, 25, 249-258.	3.7	217
35	Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. Clinical Cancer Research, 2017, 23, 3499-3509.	3.2	76
36	HER2-Specific Chimeric Antigen Receptorâ€"Modified Virus-Specific T Cells for Progressive Glioblastoma. JAMA Oncology, 2017, 3, 1094.	3.4	608

#	Article	IF	Citations
37	Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibodyâ€“Activated Chimeric Antigen Receptorâ€“Modified T Cells. Journal of Immunology, 2017, 199, 348-362.	0.4	41
38	CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Molecular Therapy, 2017, 25, 2214-2224.	3.7	378
39	Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Reports, 2017, 21, 17-26.	2.9	203
40	Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discovery, 2017, 7, 1238-1247.	7.7	204
41	Phase 1 clinical trial of adoptive immunotherapy using â€œoff-the-shelfâ€•activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy, 2017, 19, 1225-1232.	0.3	117
42	Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Molecular Therapy, 2017, 25, 2202-2213.	3.7	109
43	EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas. Methods in Molecular Biology, 2017, 1532, 255-265.	0.4	16
44	Clinical and immunological responses after CD30-specific chimeric antigen receptorâ€“redirected lymphocytes. Journal of Clinical Investigation, 2017, 127, 3462-3471.	3.9	301
45	Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 3547-3557.	0.8	367
46	Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma.. Journal of Clinical Oncology, 2017, 35, 10508-10508.	0.8	32
47	Fine-tuning the CAR spacer improves T-cell potency. OncoImmunology, 2016, 5, e1253656.	2.1	137
48	Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. Cell Reports, 2016, 17, 1453-1461.	2.9	223
49	Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy. Methods in Molecular Biology, 2016, 1441, 195-202.	0.4	20
50	Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. Journal of Allergy and Clinical Immunology, 2016, 137, 1498-1505.e1.	1.5	117
51	Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling. Blood, 2016, 128, 1851-1851.	0.6	22
52	Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2016, 128, 501-501.	0.6	2
53	Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia. Blood, 2016, 128, 1649-1649.	0.6	1
54	Fast and Efficient Gene Editing in Human Hematopoietic Cells. Blood, 2016, 128, 4704-4704.	0.6	0

#	Article	IF	Citations
55	Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood, 2015, 125, 3905-3916.	0.6	260
56	Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model. PLoS ONE, 2015, 10, e0140744.	1.1	11
57	Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir. Journal of Infectious Diseases, 2015, 212, 258-263.	1.9	86
58	Antigen-specific T cell therapies for cancer: Figure 1.. Human Molecular Genetics, 2015, 24, R67-R73.	1.4	32
59	CMV-specific T cells generated from naÃ¯ve T cells recognize atypical epitopes and may be protective in vivo. Science Translational Medicine, 2015, 7, 285ra63.	5.8	93
60	Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood, 2015, 125, 4103-4113.	0.6	188
61	Peripheral Bloodâ€“Derived Virus-Specific Memory Stem T Cells Mature to Functional Effector Memory Subsets with Self-Renewal Potency. Journal of Immunology, 2015, 194, 5559-5567.	0.4	36
62	Human Epidermal Growth Factor Receptor 2 (HER2) â€“Specific Chimeric Antigen Receptorâ€“Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. Journal of Clinical Oncology, 2015, 33, 1688-1696.	0.8	778
63	Evaluating the potential for undesired genomic effects of the <i>piggyBac</i> transposon system in human cells. Nucleic Acids Research, 2015, 43, 1770-1782.	6.5	44
64	Broadly-specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for Immunotherapy. Molecular Therapy, 2015, 23, 387-395.	3.7	46
65	Adoptive T-Cell Immunotherapy. Current Topics in Microbiology and Immunology, 2015, 391, 427-454.	0.7	48
66	Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients. Molecular Therapy, 2015, 23, 602-608.	3.7	132
67	Graft Versus Leukemia Response Without Graft-versus-host Disease Elicited By Adoptively Transferred Multivirus-specific T-cells. Molecular Therapy, 2015, 23, 179-183.	3.7	28
68	Safety of Multiple Doses of CAR T Cells. Blood, 2015, 126, 4425-4425.	0.6	5
69	Autologous HER2 CMV bispecific CAR T cells for progressive glioblastoma: Results from a phase I clinical trial.. Journal of Clinical Oncology, 2015, 33, 3008-3008.	0.8	44
70	Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years. Blood, 2015, 126, 1926-1926.	0.6	0
71	Optimizing the production of suspension cells using the G-Rex â€œMâ€• series. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14015.	1.8	71
72	Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor. Molecular Therapy, 2014, 22, 1211-1220.	3.7	145

#	Article	IF	Citations
73	Systemic Inflammatory Response Syndrome After Administration of Unmodified T Lymphocytes. Molecular Therapy, 2014, 22, 1134-1138.	3.7	28
74	Harnessing the Immune System to Potentiate Oncolytics. Molecular Therapy, 2014, 22, 239-240.	3.7	1
75	Can Treg elimination enhance NK cell therapy for AML?. Blood, 2014, 123, 3848-3849.	0.6	7
76	T lymphocytes targeting native receptors. Immunological Reviews, 2014, 257, 39-55.	2.8	34
77	Reply to S. Yuan et al. Journal of Clinical Oncology, 2014, 32, 2820-2821.	0.8	0
78	Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT. Science Translational Medicine, 2014, 6, 242ra83.	5.8	357
79	Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins. Journal of Clinical Oncology, 2014, 32, 798-808.	0.8	433
80	Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia. Cytotherapy, 2014, 16, 1257-1269.	0.3	42
81	Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells. Molecular Therapy, 2014, 22, 623-633.	3.7	113
82	Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and InÂVivo Cytokine Administration: Implications for Clinical Therapy. Biology of Blood and Marrow Transplantation, 2014, 20, 1252-1257.	2.0	71
83	Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood, 2014, 123, 3750-3759.	0.6	534
84	Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. Molecular Therapy - Oncolytics, 2014, 1, 14008.	2.0	19
85	Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood, 2014, 123, 3895-3905.	0.6	161
86	Clinical Grade Purification and Expansion of Natural Killer Cells. Critical Reviews in Oncogenesis, 2014, 19, 121-132.	0.2	56
87	T Cells Expressing CD19-Specific Chimeric Antigen Receptors Are Inhibited By Indoleamine 2,3-Dioxygenase in Tumors. Blood, 2014, 124, 2434-2434.	0.6	0
88	Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Molecular Therapy, 2013, 21, 2113-2121.	3.7	200
89	Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood, 2013, 121, 5113-5123.	0.6	507
90	Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood, 2013, 122, 2965-2973.	0.6	470

#	Article	IF	Citations
91	Clinical Responses In Patients Infused With T Lymphocytes Redirected To Target Îº-Light Immunoglobulin Chain. Blood, 2013, 122, 506-506.	0.6	6
92	T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nature Reviews Clinical Oncology, 2012, 9, 510-519.	12.5	230
93	Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials. Molecular Therapy - Nucleic Acids, 2012, 1, e55.	2.3	10
94	Adoptive transfer of virus-directed T cells: will this fly for flu?. Cytotherapy, 2012, 14, 133-134.	0.3	2
95	Optimal Xenogeneic Adoptive Transfer of Human NK Cells: Fresh NK Cells and IL-15 Administration Are Superior to Frozen NK Cells and IL-2. Blood, 2012, 120, 346-346.	0.6	1
96	Multicenter Study of â€œoff-the-Shelfâ€•Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT). Blood, 2012, 120, 457-457.	0.6	2
97	Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients. Blood, 2012, 120, 579-579.	0.6	2
98	Human papillomavirus type 16 (HPV16) E6/E7-specific cytotoxicÂT lymphocytes (CTL) for immunotherapy of HPV-associated cancer (Ca).. Journal of Clinical Oncology, 2012, 30, 2558-2558.	0.8	0
99	Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order. Blood, 2012, 120, 1912-1912.	0.6	0
100	Safety and Clinical Efficacy of Rapidly-Generated Trivirus-Directed T Cells After Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2012, 120, 223-223.	0.6	25
101	Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma. Molecular Therapy, 2011, 19, 2258-2268.	3.7	80
102	CD28 costimulation improves expansion and persistence of chimeric antigen receptorâ€“modified T cells in lymphoma patients. Journal of Clinical Investigation, 2011, 121, 1822-1826.	3.9	876
103	Combining Oncolytic Vaccinia Virotherapy with Adoptive T Cell Therapy,. Blood, 2011, 118, 4042-4042.	0.6	1
104	Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins. Blood, 2011, 118, 956-956.	0.6	1
105	Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies,. Blood, 2011, 118, 4043-4043.	0.6	0
106	Human Papillomavirus Type 16 (HPV16) E6/E7-Specific Cytotoxic T Lymphocytes (CTLs) for Immunotherapy of HPV-Associated Malignancies. Blood, 2011, 118, 1913-1913.	0.6	0
107	EBV-Induced Lymphoproliferation. Blood, 2011, 118, SCI-9-SCI-9.	0.6	0
108	Vaccination with Î"CD40L or Flagellin Gene-Modified T Cells Activates Dendritic Cells In Vivo and Induces a Potent Anti-Tumor Immune Response. Blood, 2011, 118, 1909-1909.	0.6	0

#	Article	IF	Citations
109	Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood, 2010, 115, 925-935.	0.6	721
110	Generation of Epstein-Barr virusâ€"specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood, 2009, 114, 4784-4791.	0.6	86
111	Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood, 2009, 114, 4283-4292.	0.6	311
112	IL15 Enhances Proliferation and Effector Function of Antigen-Specific Cytotoxic T Lymphocytes (CTLs) and Mitigates the Suppressive Action of Regulatory T Cells (Tregs).. Blood, 2009, 114, 4088-4088.	0.6	1
113	Cytotoxic T Lymphocytes (CTL) Specific for CMV, Adenovirus, and EBV Can Be Generated From Naive T Cells for Adoptive Immunotherapy.. Blood, 2009, 114, 504-504.	0.6	0
114	An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell Therapies.. Blood, 2009, 114, 1444-1444.	0.6	0
115	Adverse Events Following Infusion of T Cells for Adoptive Immunotherapy: A 10 Year Experience.. Blood, 2009, 114, 3212-3212.	0.6	0
116	Immune-Based Therapies Targeting Mage-A4 for Relapsed/Refractory Hodgkin's Lymphoma After Stem Cell Transplant.. Blood, 2009, 114, 4089-4089.	0.6	7
117	Monoculture-Derived T Lymphocytes Providing Multiple Virus Specificity and Anti-Leukemia Activity for Recipients of Hematopietic Stem Cells or Umbilical Cord Blood Transplants. Blood, 2008, 112, 3909-3909.	0.6	1
118	Generation of Epstein Barr Virus Specific Cytotoxic T Lymphocytes (EBVCTLs) Resistant to the Immunosuppressive Drug Tacrolimus (FK506). Blood, 2008, 112, 3536-3536.	0.6	0
119	Complete Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T Lymphocytes Targeting EBV Latent Membrane Proteins. Blood, 2008, 112, 230-230.	0.6	0
120	The â€œSide-Populationâ€•of Human Lymphoma Cells Have Increased Chemo-Resistance, Stem-Cell Like Properties and Are Potential Targets for Immunotherapy. Blood, 2008, 112, 2620-2620.	0.6	0
121	Selective Loss of a Putative Precursor Population of B-Chronic Lymphocytic Leukemia Cells Following Immunization with hCD40L/IL-2 Expressing Autologous Tumor Cells. Blood, 2008, 112, 3172-3172.	0.6	0
122	Exploiting Cytokine Secretion to Rapidly Produce Multivirus-Specific T Cells for Adoptive Immunotherapy. Blood, 2008, 112, 4594-4594.	0.6	0
123	Polyclonal PRAME-Specific Cytotoxic T Lymphocytes Generated Using Protein-Spanning Pools of Overlapping Pentadecapeptides Target Chronic Myeloid Leukemia. Blood, 2008, 112, 3899-3899.	0.6	0
124	Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood, 2007, 110, 2838-2845.	0.6	266
125	Adoptive immunotherapy for herpesviruses. , 2007, , 1318-1331.		2
126	T-Cells Redirected Against CD70 for the Immunotherapy of Hematological Malignancies.. Blood, 2007, 110, 2757-2757.	0.6	3

#	Article	IF	Citations
127	Adoptive cellular immunotherapy. , 2006, , 648-660.		0
128	Treatment of solid organ transplant recipients with autologous Epstein Barr virusâ€“specific cytotoxic T lymphocytes (CTLs). Blood, 2006, 108, 2942-2949.	0.6	241
129	Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nature Medicine, 2006, 12, 1160-1166.	15.2	536
130	Generation and Expansion of PRAME-Specific Cytotoxic T-Lymphocytes for Adoptive T-Cell Therapy of Hematological Malignancies.. Blood, 2006, 108, 2205-2205.	0.6	0
131	Immune Responses Are Induced Against Side-Population B-CLL â€œStem Cells â€• by Patient Vaccination with hCD40L/IL2 Gene Modified Tumor Cells.. Blood, 2006, 108, 2552-2552.	0.6	0
132	A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Molecular Therapy, 2005, 12, 933-941.	3.7	426
133	Genetically Modified Her2-Specific T Cells Recognize Low and High Her2 Expressing Breast Cancer Cells.. Blood, 2005, 106, 5540-5540.	0.6	0
134	The Clinical Use of Donor-Derived Virus-Specific Cytotoxic T Lymphocytes Reactive Against Cytomegalovirus (CMV), Adenovirus and Epstein Barr Virus (EBV).. Blood, 2005, 106, 81-81.	0.6	0
135	The Use of Autologous LMP2-Specific Cytotoxic T Lymphocytes (CTL) for the Treatment of Relapsed EBV-Positive Hodgkin Disease and Non-Hodgkin Lymphoma.. Blood, 2005, 106, 773-773.	0.6	0
136	Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease. Journal of Experimental Medicine, 2004, 200, 1623-1633.	4.2	371
137	Three-Module Signaling Endo-Domain Artifical T-Cell Receptor Which Transmits CD28, OX40 and CD3-Î¶ Signals Enhances IL-2 Release and Proliferative Response in Transduced Primary T-Cells.. Blood, 2004, 104, 1747-1747.	0.6	2
138	Fas Down-Modulation in Epstein Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes (CTLs) Reduces Their Sensitivity to Fas/Fasl-Induced Apoptosis.. Blood, 2004, 104, 2647-2647.	0.6	0
139	Retrovirus-Transduced T Cell Blasts Have Not Only Antigen-Presenting Capabilities but Also Suppressor Regulatory T Cell-Inducing Capability.. Blood, 2004, 104, 3855-3855.	0.6	0
140	New insights into EBV-associated post-transplant lymphoproliferative disease. Lancet, The, 2003, 361, 192-193.	6.3	6
141	Counting EBV and T cells to predict PTLD. Blood, 2003, 101, 4227-4228.	0.6	2
142	Adapting a transforming growth factor Î²â€“related tumor protection strategy to enhance antitumor immunity. Blood, 2002, 99, 3179-3187.	0.6	310
143	An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood, 2001, 97, 835-843.	0.6	249
144	Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. International Journal of Cancer, 2001, 93, 706-713.	2.3	80

#	Article	IF	Citations
145	Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. , 1999, 14, 154-156.		29
146	Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Hodgkin Disease. Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas. Human Gene Therapy, 1998, 9, 1237-1250.	1.4	24
147	Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virusâ€“Induced Lymphoma in Allogeneic Transplant Recipients. Blood, 1998, 92, 1549-1555.	0.6	269
148	Longâ€“term restoration of immunity against Epsteinâ€“Barr virus infection by adoptive transfer of geneâ€“modified virusâ€“specific T lymphocytes. Nature Medicine, 1996, 2, 551-555.	15.2	820